BNP Paribas Financial Markets Acquires 71,721 Shares of Personalis, Inc. (NASDAQ:PSNL)

BNP Paribas Financial Markets lifted its holdings in Personalis, Inc. (NASDAQ:PSNL - Free Report) by 53,126.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 71,856 shares of the company's stock after buying an additional 71,721 shares during the period. BNP Paribas Financial Markets owned about 0.10% of Personalis worth $415,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in PSNL. Stifel Financial Corp lifted its holdings in shares of Personalis by 25.0% during the fourth quarter. Stifel Financial Corp now owns 25,000 shares of the company's stock worth $144,000 after purchasing an additional 5,000 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Personalis by 2,827.0% in the fourth quarter. JPMorgan Chase & Co. now owns 5,854 shares of the company's stock valued at $34,000 after buying an additional 5,654 shares in the last quarter. Ameriprise Financial Inc. grew its position in shares of Personalis by 38.3% during the fourth quarter. Ameriprise Financial Inc. now owns 34,407 shares of the company's stock worth $199,000 after buying an additional 9,535 shares in the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its holdings in Personalis by 66.6% in the fourth quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 25,168 shares of the company's stock valued at $145,000 after purchasing an additional 10,065 shares in the last quarter. Finally, Olympiad Research LP acquired a new stake in shares of Personalis during the fourth quarter worth about $59,000. 61.91% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on PSNL. Craig Hallum initiated coverage on Personalis in a report on Monday, March 17th. They issued a "buy" rating and a $8.00 price target for the company. Needham & Company LLC reissued a "buy" rating and issued a $7.00 price objective on shares of Personalis in a report on Thursday, April 10th. HC Wainwright raised their price objective on Personalis from $8.00 to $9.00 and gave the stock a "buy" rating in a research note on Wednesday, May 7th. Finally, Guggenheim started coverage on Personalis in a research report on Thursday, May 15th. They set a "buy" rating and a $6.00 price objective for the company. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $7.67.

Personalis Stock Up 1.3%

Shares of NASDAQ:PSNL traded up $0.06 during mid-day trading on Friday, reaching $4.65. 60,470 shares of the stock were exchanged, compared to its average volume of 1,013,584. The stock's 50 day simple moving average is $3.96 and its 200-day simple moving average is $4.45. Personalis, Inc. has a one year low of $1.14 and a one year high of $7.20. The company has a market cap of $410.62 million, a P/E ratio of -2.76 and a beta of 1.83.

Personalis (NASDAQ:PSNL - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.05. The firm had revenue of $20.61 million during the quarter, compared to the consensus estimate of $17.41 million. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. Analysts anticipate that Personalis, Inc. will post -1.4 EPS for the current fiscal year.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.